Although doxorubicin has been gradually replaced by new systemic drugs in the treatment of HCC, this compound promotes SNHG1 retention in the nucleus of human cells, by promoting binding of p53 with nucleolin. Here, TP53 is linked to hepatocellular carcinoma.